To highlight recent advances in understanding the clinical manifestations and molecular genetics of myotonic syndromes, with particular emphasis on the myotonic dystrophies.
Introduction
Myotonia is a state of hyperexcitability in muscle ®bers in which voluntary or electromechanical activation is followed by runs of repetitive action potentials, causing a delay in muscle relaxation. Genetic and physiological studies have shown that defects in either of two ion channels can cause myotonia. Mutations in the gene encoding ClC-1, a chloride channel that is highly expressed and speci®c to skeletal muscle, cause generalized myotonia (myotonia congenita). Myotonia is also caused by mutations in SCN4A, the gene encoding the alpha subunit of the skeletal muscle sodium channel. However, the physiological basis for myotonia in myotonic dystrophy (DM), the most common myotonic disorder, has not been determined. This review will focus on recent advances in the genetics and pathogenesis of the myotonic dystrophies and the non-dystrophic myotonias. A more complete discussion of the clinical manifestations of DM and other myotonic syndromes can be found in a recent monograph by Harper [1].
The myotonic dystrophies
The nosology of DM is in a state of¯ux. DM can be regarded as a clinical syndrome that includes subtypes designated myotonic dystrophy type1 (DM1), myotonic dystrophy type 2 (DM2), and so forth, each of which is a single-gene entity. This terminology was recommended by an international panel [2] and will be followed in this review. Alternatively, some experts reserve the term myotonic dystrophy' for the monogenic disorder that was originally described by Steinert, and prefer a different designation for variants, such as proximal myotonic myopathy (PROMM), which are clinically and genetically distinct. This terminology is discussed in more detail below.
DM is a multi-system disease characterized by myotonia, progressive muscle wasting, and a range of potential systemic manifestations that may include cataracts, cardiac conduction defects, gonadal atrophy, and neuropsychiatric impairment. The genetic basis for DM1, the most common form of DM, is an expansion of CTG repeats in the DMPK gene on chromosome 19 [3] . The mutation that causes DM2 (PROMM) was recently discovered to be an expansion of CCTG repeats in the ZNF9 gene on chromosome 3 [4
. . ]. Both of these DNA expansion mutations are highly unstable, as shown by changes in the length of the repeat in successive generations and even in somatic cells of an individual. It appears that some families with a DM-like disorder have neither the DM1 nor the DM2 mutations, which suggests the existence of DM type 3.
Clinical manifestations of myotonic dystrophy type 1
Approximately 10% of patients with DM1 present in infancy with neonatal hypotonia, feeding and respiratory dif®culties, and mental retardation in those who survive into childhood. Infants with congenital DM1 have very large repeat expansions (41000 CTG repeats). Almost invariably, these infants have inherited the disease from their mother. This maternal bias in transmitting DM1 re¯ects a sex difference in the dynamics of repeat instability during gametogenesis. It appears that the likelihood of generating very large repeat expansions is much greater during oogenesis than spermatogenesis [5] . However, recent case reports have indicated that an affected father can occasionally transmit congenital DM1. Zeesman et al. [6] recently reported an infant boy with congenital DM (1800 CTG repeats) whose father had an asymptomatic CTG expansion (65 repeats). This report is an extreme example of the intergenerational increase in repeat length that usually occurs in DM1, and the corresponding increase in disease severity in offspring (the phenomenon of anticipation). In counselling men with DM1, it is prudent to mention the small risk of transmitting congenital disease. Intergenerational instability of the repeat can also work in the opposite direction. Amiel et al. [7] recently reported an extreme example of this phenomenon whereby the expanded repeat when transmitted from the father (200 repeats) to his child reverted back to a normal size (30 repeats).
Cardiac arrhythmia, especially heart block caused by progressive degeneration of the conduction system, is the second leading cause of death in DM1 [8] . However, the indications for pacemaker placement and the value of genetic analysis in predicting cardiac events have not been clearly de®ned. Clarke et al. [9 . ] prospectively followed 73 DM1 patients with annual clinical and electrocardiography evaluations. Patients with larger expansions of CTG repeats (41000 repeats) were at increased risk of intraventricular conduction delay at baseline and showed more rapid progression of the conduction defect. This result is consistent with previous work showing that various measures of disease severity are roughly correlated with the size of the expanded repeat in circulating leukocytes. However, the range of severity that can occur with a particular repeat size is broad.
Instability of the expanded CTG repeat in myotonic dystrophy type 1 ] showed that instability of expanded CAG/CTG repeats in mice can occur independently of DNA replication by a process that presumably involves DNA repair. Taken together, these results and previous studies [16] raise the possibility that the length of the expanded CTG repeat may continue to increase even in non-dividing cells of mature skeletal muscle and brain, and that drug treatment to modify this process may be an appropriate therapeutic strategy in DM1.
Molecular mechanism of myotonic dystrophy type 1: an evolving concept
More than 10 years have passed since the discovery of the DM1 mutation; however, the fundamental nature of the disease process is still debated. The protein kinase encoded by DMPK is expressed in brain and muscle (skeletal, cardiac, and smooth), but its function in these tissues is not understood. Recent papers from Muranyi et al.
[17] and Shimizu et al. [18] suggested that DMPK is involved in regulating components of the cytoskeleton, and previous work has shown a role in calcium homeostasis [19] . However, elucidating the function of this kinase may not be the main avenue to understanding the pathogenesis of DM1. The expanded repeat lies in the 3' untranslated region of the DMPK gene, a region that is transcribed into RNA but not translated into protein.
The expansion mutation in this position does not cause the production of altered or dysfunctional DMPK protein, which is the effect that is usually expected in dominantly inherited diseases. However, expansion of the CTG repeat has other effects, including effects on other genes at the DM1 locus. A major focus of recent research has been to determine which of these effects leads to the disease manifestations, or if the disease results from a combination of several mechanisms, to determine which manifestations are caused by a particular effect.
Effects on adjacent chromatin structure
Expansion of the CTG repeat alters the conformation of chromatin in the vicinity of the DMPK gene [20] . One consequence of this change is that the expression of a neighbouring gene, SIX5, is partly suppressed [21, 22] . Although it is clear that SIX5 functions as a transcription factor, it has been uncertain whether lowering the expression of this gene could explain any of the manifestations of DM1. Recent studies have suggested that the silencing of SIX5 is unlikely to be a major factor in the pathogenesis of DM. When the expression of SIX5 was eliminated in mice, no effect on skeletal muscle was observed [23] . The mice, however, did develop premature cataracts [23, 24] , raising the possibility that silencing of the Six5 gene may contribute to the development of cataracts in DM1. A recent paper by Filippova et al. [25 . ] also suggested that changes in chromatin structure, and the resulting misregulation of genes in the vicinity, could be relevant to the defects of muscle and brain development that occur in congenital DM1.
Effects on expression of DMPK gene
Expansion of the CTG repeat also reduces the expression of DMPK itself, although the mechanism for this effect is entirely different. The expanded repeat is transcribed and it appears in the DMPK messenger RNA as a large tract of CUG repeats near the 3' end (polyA tail) of the transcript. However, instead of being exported to the cytoplasm, this mutant mRNA is retained in the nucleus in multiple discrete foci [26, 27] , referred to here as ribonuclear inclusions. The amount of DMPK protein in the cells is presumably reduced because less DMPK mRNA is available for translation (i.e. only the mRNA from the normal allele can be translated). Recent studies from Berul and coworkers [28] have suggested that reduced expression of DMPK may contribute to cardiac disease, because mice de®cient in this kinase develop abnormalities of cardiac conduction that are similar to those seen in patients with DM1. However, knocking out the DMPK gene in mice does not lead to myotonia or progressive muscle degeneration [29, 30] , suggesting that a mechanism other than DMPK de®ciency is mainly responsible for the disease manifestations in skeletal muscle.
RNA-mediated disease mechanism
Recent studies have identi®ed a surprising effect of the DM1 mutation. It now appears likely that the RNA produced from the mutant DMPK gene has a toxic effect on muscle cells. This mechanism was not suspected initially because there was no precedent in mammalian genetics for considering that a mutant mRNA could acquire a toxic function. We derived a transgenic mouse model in which expanded CUG repeats were expressed at high levels in skeletal muscle [31] . These mice developed ribonuclear inclusions, myotonia, and histological changes in muscle similar to human DM1. However, despite having a large burden of expanded CUG repeats in muscle nuclei, the mice did not develop severe muscle wasting, leaving open the possibility that mechanisms other than RNA gain-of-function are required for this aspect of the disease. Because expression of the transgene was restricted to skeletal muscle, it was unclear whether expression of expanded CUG repeats could produce the cardiac, brain, or ocular manifestations of DM1. Seznec et al. [32 . ] recently reported a second transgenic model of DM1 in which an expanded CUG repeat was expressed in a wider range of tissues and in the natural context of DMPK mRNA. These mice developed abnormalities of the tau protein in the brain, which are reminiscent of those that occur in DM1, suggesting that a toxic gain-of-function by mutant RNA may also occur in the brain.
RNA binding proteins
When studied in vitro, expanded CUG repeats have the unusual biophysical property of forming long hairpin loops that have extended regions of double-stranded RNA [33, 34] . However, we do not have information about the structure of expanded CUG repeats in cells, nor do we have a clear understanding of why mRNAs that contain this repeat sequence are retained in the nucleus and recruited into ribonuclear inclusions. Furthermore, it is not clear whether the toxic effect is caused by RNA in the ribonuclear inclusions or a fraction of the mutant RNA that remains free in the nucleoplasm.
One possibility is that mutant RNA, which contains an expanded CUG repeat, has a deleterious effect on RNA metabolism by sequestering essential RNA binding proteins. CUG binding protein 1 (CUGBP1) is a protein ®rst identi®ed through its ability to bind non-expanded CUG repeats in vitro [35] . This protein and related RNA binding proteins have been implicated in the regulation of splicing [36] 
Abnormal regulation of alternative splicing
Previous studies have established that the regulation of alternative splicing for the cardiac troponin T gene is abnormal in DM1 cardiac tissue, and that this alteration can result from the expression of expanded CUG repeats [36] . However, effects on cardiac troponin T gene isoforms have not been implicated in the pathogenesis of cardiac dysfunction. Recent studies by the same investigative group have revealed abnormal alternative splicing of the insulin receptor. The insulin receptor is expressed as two isoforms that differ in their response to insulin binding. The main isoform expressed in skeletal muscle includes exon 11. This isoform encodes receptor protein that has a higher signalling capacity, be®tting the importance of skeletal muscle in glucose disposal. The isoform that is expressed in most non-muscle tissues does not include exon 11. This isoform encodes insulin receptor that has lower signalling capacity. Savkur et al.
[38
. . ] found that the exon 11 skipping (low signalling) isoform is preferentially produced in DM1 skeletal muscle. This alteration was consistent in each of 17 DM1 patients, but not in disease controls, suggesting that the mis-splicing of insulin receptor pre-mRNA could potentially explain the insulin resistance that is often associated with DM1. ] analysed tau mRNA and protein in autopsied brain tissues from ®ve patients with DM1, and found an increased frequency of the isoforms generated by skipping exon 2 . Furthermore, an abnormal pro®le of tau proteins was also observed in mice that express a human DMPK transgene containing an expanded CTG repeat [32 . ]. These observations raise the possibility that altered stoichiometry of tau isoforms could be involved in producing the behavioral and cognitive alterations in DM1.
Taken together, the studies of RNA processing support the proposal by Philips et al. [36] that abnormal regulation of alternative splicing is fundamentally involved in the pathogenesis of DM1. Further research is needed to clarify the role of CUGBP1 and muscleblind proteins in this process.
Muscle maldevelopment in congenital myotonic dystrophy type 1
The hypotonia in infants with congenital DM1 is thought to involve a delay in differentiation and maturation of the skeletal muscle. To investigate this delay, Furling et al. [49 . ] established myoblast (muscle precursor cell) cultures from three fetuses affected by congenital DM1. The size of the expanded CTG was approximately 2300 repeats in early passage cultures, and further expansion was observed during proliferation in vitro. The congenital DM1 myoblasts had reduced proliferative capacity (i.e. during serial passage the DM1 myoblasts exhausted their replicative potential earlier than controls). Under conditions of growth factor deprivation that induced myoblast fusion and the formation of multinucleate myotubes in normal controls, the fusion of DM1 myoblasts was much less ef®cient and the myogenic differentiation of DM1 myotubes was less complete. Both myoblasts and myotubes from DM1 fetuses showed ribonuclear inclusions. The authors proposed that nuclear accumulation of the mutant DMPK mRNA causes premature senescence and impaired differentiation of DM1 myoblasts, and suggested that the muscle hypotrophy and hypotonia in congenital DM could arise through a similar mechanism. It is notable that a similar reduction of proliferative capacity was observed in lymphoblastoid cell lines derived from DM1 patients ] suggested that both the expanded CUG repeat and other regions of the DMPK mRNA were necessary for this inhibition. Taken together, such studies suggest that RNA gain-of-function plays a role in producing the developmental defects in congenital DM1. It is noteworthy, however, that the maldevelopment of skeletal muscle or brain has not been observed in any of more than a dozen attempts to make transgenic or knockout mouse models of DM1.
Myotonic dystrophy type 2 (PROMM)
Previous genetic studies have identi®ed a subset of patients with DM-like phenotypes who did not have the CTG expansion mutation or any point mutations in the DMPK gene [53, 54] . Although the clinical manifestations in these patients were unusual in that weakness was mainly in the proximal muscles, the pattern of inheritance (autosomal dominant), muscle histology, myotonia, cataracts, testicular atrophy, and occasional cardiac conduction disease were unmistakably similar to DM1. Ricker et al.
[54] coined the term`proximal myotonic myopathy' (PROMM) to emphasize the early involvement of proximal muscles in these kindreds. Other investigators proposed the terms`proximal myotonic dystrophy ' [55] or`myotonic dystrophy type 2' [56] to describe families that had prominent dystrophic changes on muscle biopsy or the clear involvement of distal muscle groups. Ranum et al.
[57] established a linkage to chromosome 3q in a large kindred with notable distal weakness. Subsequently, it was shown that kindreds with proximal weakness were linked to this same (DM2) locus [58] . Very recently, Liquori et al. [4 . . ] identi®ed a DNA expansion mutation at this locus, which proved to be an expanded CCTG repeat in intron 1 of the ZNF9 gene. ZNF9 is believed to encode an RNA binding protein that is expressed in many different tissues.
The discovery of the DM2 mutation is still too recent to obtain a clear picture of the range of clinical manifestations that can occur in this disorder. Current information suggests that DM2 can sometimes produce substantial weakness of distal muscle groups, such as ®nger¯exors [56] . However, the predominant weakness in most individuals with DM2 is in the proximal limb muscles and neck¯exors. Experience suggests that cataracts and male hypogonadism are no less prominent in DM2 than in DM1, but that major disease of the cardiac conduction system is less common, and the overall prognosis is more favorable [59] . Further study is needed to determine the frequency of different systemic complications in DM2. At present there is no compelling evidence that DM2 can produce embryonic lethality or congenital disease, but this possibility needs to be rigorously examined. If congenital disease does exist in DM2, it appears to be much less common than in DM1. ]. In our experience the ribonuclear inclusions are larger and more intense in DM2 than in DM1, as would be expected given the greater abundance of ZNF9 than DMPK mRNA and the respective sizes of the expanded repeats (up to 15 000 base pairs in DM1 versus 44 000 base pairs in DM2). Although these observations support the idea that RNA gain-of-function is responsible for both the muscle and the non-muscle manifestations in DM, research on the disease mechanism in DM2 is at a very early stage.
Non-dystrophic myotonic syndromes
The non-dystrophic myotonic syndromes are caused by conventional point mutations or deletions in the genes that encode the skeletal muscle chloride or sodium channels.
Chloride channel myotonia
Skeletal muscle is unusual among excitable tissues in expressing high levels of voltage-gated chloride channels. A single channel, ClC-1, accounts for more than 75% of this chloride conductance. Mutations that eliminate functional ClC-1 or alter its voltage activation characteristics can cause recessive or dominantly inherited generalized myotonia [60] . These mutations are not generally accompanied by progressive muscle degeneration, although minor histological changes and muscle wasting can occur. Nagamitsu et al. [61] reported a variant`dystrophic' phenotype characterized by progressive myopathy. Both ClC-1 alleles were affected in this individual, but the mutations in each allele were different (a compound heterozygote). This case report raises the possibility that chronic loss of chloride conductance may be injurious to muscle ®bers in some patients, or that certain mutant ClC-1 proteins have a toxic effect on skeletal muscle.
Dutzler et al. [62 . ] recently published the ®rst X-ray crystallography structure of a bacterial chloride channel. Because the amino acid sequences of bacterial and human chloride channels are conserved, the structure of human ClC-1 is likely to be similar. That study con®rmed that the functional channel is a homodimer, and revealed detailed information about the conduction pore, an important step towards understanding the effects of different mutations on ClC-1 structure and function.
Sodium channel myotonia
Clinical syndromes caused by mutations in the gene encoding the alpha subunit of the skeletal muscle sodium channel (SCN4A) include potassium-aggravated myotonia, paramyotonia congenita, and hyperkalemic periodic paralysis. A total of 24 missense mutations have been identi®ed in SCN4A. All mutations studied to date cause altered channel properties so that the decay of sodium current (fast inactivation) is either slow (myotonia) or incomplete (weakness). Most mutations are clustered in domain III or IV of the channel protein, the regions involved in fast inactivation. Wu et al. [63] recently identi®ed a novel missense mutation (L266V) in domain I, associated with cold-aggravated myotonia. This mutation produces a very subtle change in the channel protein, yet the authors showed that the fast inactivation of the mutant channel is suf®ciently impaired to cause myotonia.
Recent progress in treatment of myotonic dystrophy type 1
Excessive daytime sleepiness is a common symptom in DM1. Moda®nil is proposed to regulate the sleep±wake cycle by the selective activation of orexin-containing neurons in the hypothalamus. In an open-label study, Damian and colleagues [64 . ] treated nine patients moderately affected by DM1 with moda®nil (200± 400 mg/day) for 4 months. All patients reported a major improvement in daytime sleepiness. None experienced any side-effects. Although these results raise the possibility that moda®nil may be a promising treatment for hypersomnia in DM1, controlled trials are needed.
Conclusion
DNA expansion mutations are responsible for the distinctive clinical manifestations of DM1 and DM2. Further research is needed to determine if there are types of DM other than DM1 or DM2. A growing body of evidence indicates that ribonuclear inclusions are the pathological hallmarks of DM, and that the disease process involves a toxic gain-of-function by the mutant RNA. Some manifestations of DM1, such as insulin resistance in skeletal muscle may result from transinterference with RNA processing. These recent advances lay the groundwork for investigating the major aspects of the DM phenotype, such as myotonia, muscle wasting, delayed muscle maturation in congenital DM1, cardiac arrhythmia, and central nervous system dysfunction. Devising strategies to overcome the toxicity of mutant RNA will be a fertile area for future research.
